Survival and outcomes for co-infection of chronic hepatitis C with and without cirrhosis and COVID-19: A multicenter retrospective study

Table 1 Baseline demographic features of patients (n = 125 patients)

Item	n (%)
Egyptian governorate
Cairo	78 (62.4)
Al-Menofeya	17 (13.6)
Giza	14 (11.2)
Al-Qalubya	9 (7.2)
Al-Behera	7 (5.6)
Age (yr)
20 to 30	1 (0.8)
30 to 40	6 (4.8)
40 to 50	10 (8.1)
50 to 60	31 (25.0)
60 to 70	35 (28.2)
70 to 80	35 (28.2)
80 to 90	6 (4.8)
Gender
Male	86 (68.8)
Female	39 (31.2)
Cigarette smoking	10 (8.0)
History of contact with COVID-19 case	32 (25.6)
Diabetes mellitus	52 (41.6)
Hypertension	52 (41.6)
Direct-acting antiviral therapy treatment
Not previously treated	108 (86.4)
Sustained virological response	17 (13.6)
COPD	1 (0.8)
Coronary artery disease	12 (9.6)
Acute kidney injury	1 (0.8)
Chronic renal insufficiency	8 (6.4)
Heart failure	2 (1.6)
Bronchial asthma	1 (0.8)
CT pattern	1 (0.8)
Consolidations and ground-glass opacities	31 (24.8)
Ground-glass opacities	94 (75.2)
Lesion distribution on CT
Bilateral	122 (97.6)
Unilateral	3 (2.4)
COVID-19 case severity
Moderate	86 (68.8)
Severe	39 (31.2)
Admission zone
ICU	24 (19.2)
Intermediate care	6 (4.8)
Ward	95 (76.0)

COVID-19: Coronavirus disease 2019; COPD: Chronic obstructive pulmonary disease;

CT: Computed tomography; ICU: Intensive care unit.